Jamjoom Pharmaceuticals Factory Company, together with its subsidiaries, engages in the manufacture and distribution of pharmaceutical and consumer products in the Kingdom of Saudi Arabia, Gulf, Iraq, Egypt, North Africa, and internationally. It provides human medicines; nutraceuticals; antibiotics; general analgesics; medicines for treatment of cough, allergy, asthma, heart diseases, blood pressu...
Jamjoom Pharmaceuticals Factory reported revenue of 1.32 billion SAR for fiscal year 2024, up 19.8% from fiscal year 2023, and net income of 356.52 million SAR. In Q2 2025 (the quarter ended June 30, 2025) revenue was 396.22 million SAR, up 14.6% from a year before. Its largest business segment, Pharmaceutical Products, brought in 86% of segment revenue in fiscal year 2025; Kingdom of Saudi Arabia was the largest region with 66%.
Figures from company filings; latest fiscal year ended December 31, 2024.
No profile data available.